MADS34 Antibody

Biological Function of MADS34

MADS34, encoded by the LOC_Os03g54170 gene in rice, belongs to the MADS-domain transcription factor family. It governs:

• Panicle meristem identity: MADS34 works redundantly with other MADS-box genes (e.g., MADS15) to specify floral structures .

• Epigenetic regulation: MADS34 expression is modulated by histone methylation marks (H3K27me3 and H3K4me3), which are dynamically regulated by enzymes like SDG711 (a histone methyltransferase) and JMJ703 (a demethylase) .

• Inflorescence architecture: Mutations in MADS34 lead to reduced panicle size and aberrant floral organ development .

Research Findings on MADS34 Regulation

Key insights into MADS34's regulatory mechanisms include:

Epigenetic Modulation

SDG711-mediated H3K27me3 deposition represses MADS34 in the inflorescence meristem (IM), while JMJ703 removes these marks to activate transcription during floral transition . Knockdown of SDG711 reduces H3K27me3 levels at the MADS34 locus, enhancing its expression (Table 1) .

Table 1: H3K27me3 Dynamics at MADS34 in Rice Inflorescence Meristems

Data source:

Protein Interactions

MADS34 forms heteromeric complexes with other MADS-domain proteins (e.g., SEP3, AP1) to regulate target genes. Chromatin immunoprecipitation (ChIP) studies in rice and barley homologs (e.g., HvMADS1) reveal binding to CArG-box motifs in promoters of genes involved in floral development .

Applications of MADS34 Antibody in Plant Research

The antibody is utilized in:

• Western blotting: Detecting MADS34 protein levels in transgenic rice lines with altered histone methylation .

• Immunoprecipitation (IP): Identifying interaction partners, such as chromatin remodelers (e.g., CHR4, CHR17) and transcription factors (e.g., AP1, SEP3) .

• ChIP-seq: Mapping genome-wide binding sites of MADS34 to elucidate its regulatory network .

Development of Recombinant MADS34 Antibodies

Modern antibody engineering strategies, as seen in therapeutic monoclonal antibodies (mAbs) , inform the design of MADS34 antibodies:

• Recombinant production: CDR grafting onto stable human frameworks minimizes immunogenicity while retaining specificity .

• Developability optimization: Libraries using clinical antibody scaffolds (e.g., abrilumab, crenezumab) enhance stability and yield .

Future Directions

Ongoing research aims to:

• Characterize MADS34’s role in stress responses using CRISPR-edited rice lines.

• Engineer bispecific antibodies to study MADS34 interactions with other transcription factors .